JPMorgan Chase & Co. Cuts Medline (NASDAQ:MDLN) Price Target to $46.00

Posted by Geri Gentry on Aug 15th, 2026

Medline (NASDAQ:MDLN – Free Report) had its target price trimmed by JPMorgan Chase & Co. from $53.00 to $46.00 in a report released on Wednesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other brokerages also recently commented on MDLN. Weiss Ratings raised Medline from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, August 6th. Truist Financial lowered their target price on Medline from $56.00 to $47.00 and set a “buy” rating for the company in a report on Thursday, August 6th. BTIG Research restated a “buy” rating and set a $55.00 price target on shares of Medline in a research note on Friday, July 31st. BMO Capital Markets restated an “outperform” rating and issued a $47.00 price objective on shares of Medline in a report on Thursday, August 6th. Finally, Royal Bank Of Canada cut their price objective on shares of Medline from $53.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.42.

Read Our Latest Analysis on Medline

Medline Trading Up 0.4%

Shares of MDLN stock opened at $35.74 on Wednesday. Medline has a 52-week low of $32.81 and a 52-week high of $50.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33. The firm has a market capitalization of $46.99 billion and a PE ratio of 45.24. The stock has a fifty day simple moving average of $38.30 and a two-hundred day simple moving average of $41.39.

Medline (NASDAQ:MDLN – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.18. The firm had revenue of $7.68 billion for the quarter. On average, analysts predict that Medline will post 1.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Private Ltd Gic sold 590,284 shares of Medline stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $35.58, for a total value of $21,002,304.72. Following the sale, the insider owned 24,402,482 shares in the company, valued at $868,240,309.56. This trade represents a 2.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the sale, the insider owned 23,899 shares in the company, valued at approximately $878,766.23. The trade was a 80.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 2,938,896 shares of company stock worth $104,656,454. Corporate insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

A number of hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in Medline during the second quarter worth $40,430,000. E. Ohman J or Asset Management AB purchased a new stake in Medline during the 2nd quarter worth approximately $508,000. GAMMA Investing LLC lifted its holdings in Medline by 68.3% during the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after buying an additional 254 shares in the last quarter. Parallel Advisors LLC raised its position in Medline by 1,073.3% in the 1st quarter. Parallel Advisors LLC now owns 5,280 shares of the company’s stock valued at $235,000 after purchasing an additional 4,830 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. purchased a new stake in shares of Medline in the 1st quarter valued at approximately $1,048,000.

About Medline

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.